X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
X4 Pharmaceuticals, focused on innovative therapies for rare hematology diseases, announced its management will present at the 2026 Jefferies Global Healthcare Conference. The company specializes in CXCR4 biology and has an approved drug, XOLREMDI®, for WHIM syndrome. It is currently conducting a pivotal Phase 3 trial for mavorixafor in chronic neu…